LungLife AI

Company Profile

Company website
Pharmaceuticals and Biotechnology (Biotechnology)
LungLife is a developer of clinical diagnostic solutions for lung cancer enhanced by artificial intelligence. The Company’s core technologies are integrated in the LungLB® test, which is intended to be used as a tool to provide physicians with additional information to help in the decision-making process for people with indeterminate lung nodules that may be lung cancer following a CT scan.

Investor Access

08 Aug
Event information

The Company will announce its unaudited half-year results for the six months ended 30 June 2023 on Tuesday 8 August 2023 at 16:30 BST.

Investors can sign up to Investor Meet Company for free and add to meet Lung life AI via the following link:

Tuesday 8 August 2023 at 16:30 BST
Financial Calendar
 Event Date
Year End31 December
Half  Year End30 June
Preliminary Results*September
Interim Results*March

* Months based on previous announcements of this kind